Dutasteride doses matter for hair loss treatment and are more effective than finasteride. RU58841 is suggested for better gains, but side effect profiles should be considered.
Significant hair regrowth was achieved using a topical combination of 0.3% finasteride and 6% minoxidil, with weekly dermastamping and ketoconazole shampoo, without side effects. Others suggested additional treatments like red light therapy and PRP.
Stem cell therapy shows promise in treating hair loss by mimicking DHT-resistant cells from the back of the head. Traditional treatments like finasteride are also discussed, but stem cells could potentially offer a more permanent solution.
Exosomes are being considered for hair regrowth, with some users reporting initial improvement. One user moved on to using dutasteride and oral minoxidil with positive results.
The user is frustrated with hair loss despite using minoxidil, topical finasteride, and topical dutasteride, and is considering other options like oral treatments, SMP, or hair systems. They feel demoralized and are struggling with self-esteem and social interactions due to their thinning hair.
The user is experiencing increased hair loss despite using finasteride and oral minoxidil and is hesitant to switch to dutasteride due to side effects and family planning concerns. Alternatives suggested include dutasteride, microneedling, and addressing stress or nutrient deficiencies.
A 47-year-old user shared their 6-month hair loss treatment results using a Fin/Min spray and weekly dermarolling. They experienced scalp irritation with other products but found success with the Hims Fin/Min spray, noting improvements around the 5th month.
PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
The conversation is about creating a higher concentration of the newly FDA-approved hair loss treatment, Clascoterone (Winlevi), through compounding pharmacies and possibly organizing group purchases. Some users are unfamiliar with Winlevi and are asking for an explanation of the drug.
Oral Dutasteride and topical Minoxidil significantly improved hair regrowth over nine months. Other users shared mixed results and side effects with treatments like oral Minoxidil and Finasteride.
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
Redensyl, which is a topical alternative to Minoxidil for hair loss. It may have advantages such as not making the hair greasy and lasting longer after discontinuing use than minoxidil. There are some positive reports from users, but also some negative ones, so it's unclear how effective this treatment will be in comparison to Minoxidil and other treatments like Finasteride or RU58841.
The post and conversation are about the role of the enzyme 3alpha-hydroxysteroid reductase in hair loss and the potential of compounds like procyanidin B2 and sulforaphane to boost its activity for hair regrowth. Further research is needed to develop effective treatments based on this theory.
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.
Experimenting with the effects of creatine and finasteride on DHT levels, as well as a discussion regarding the potential link between creatine supplementation and hair loss.
The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.
Topical minoxidil being a difficult product to apply, with users considering finasteride, RU58841, and oral minoxidil as alternative treatments for diffuse thinning hair. Other advice includes shaving the head in the first 3 months of using minoxidil and finding ways to apply it without saturating the hair.
A double-blind clinical study that found ingestion of tocotrienols resulted in a 34.5% increase in hair regrowth compared to the placebo group, and discussion about potential side effects and cost of supplementation with vitamin E pills. The conversation noted that it may be more effective than commonly used treatments like minoxidil and finasteride.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
User DeadRay9 reports good progress on finasteride and ketoconazole, with irregular microneedling. They take 1.25mg finasteride, experienced increased libido, and saw improvements at 3-5 months.
Finasteride is seen as risky for men due to side effects like erectile dysfunction, while hormonal birth control for women is normalized despite its side effects. The discussion points out a double standard influenced by societal and gender norms.
This conversation is about a user who has been using topical finasteride and minoxidil for 6 months and has seen great results, with some side effects. Others have shared their progress and advice on how to further maximize the effectiveness of the treatments.
Oral minoxidil can cause rare facial bloating, especially at higher doses and in women. Reducing sodium intake, drinking more water, and adjusting the dose can help manage side effects.
Hairgrowth caps and helmets using low-level laser therapy (LLLT) show potential for treating androgenetic alopecia, but more research is needed. Users often combine these devices with treatments like minoxidil and finasteride for better results.
Hairgrowth relies on mechanical forces, not just chemicals, with tissue acting like a motor. Minoxidil and finasteride help, but maintaining tissue elasticity and addressing mechanical issues are essential.
The user started using topical minoxidil and recently added oral finasteride to their routine, seeing some progress but seeking advice on further hairline improvement. Other users shared their positive experiences with minoxidil and finasteride, suggesting patience and a simplified routine for better results.
Hairgrowth progress using Propecia, Minoxidil, dermarolling, ketoconazole shampoo, and vitamins. Noticeable hairgrowth in temples after 3 months and 10 days.
Adipose-derived stem cells with ATP improved hair regrowth in male and female mice with androgenetic alopecia. The most effective treatments were low dose stem cells with ATP for males and medium dose stem cells with non-liposomal ATP for females.